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Background: Interleukin 12B (IL12B) gene polymorphisms have been linked to several inflammatory diseases, but
their role in the development of Graves ophthalmopathy (GO) in Graves disease (GD) patients is unclear. The
purpose of this study was to investigate the disease association of IL12B single nucleotide polymorphisms (SNPs).
Methods: A Taiwan Chinese population comprising 200 GD patients with GO and 271 GD patients without GO was
genotyped using an allele-specific extension and ligation method. Hardy-Weinberg equilibrium was estimated using
the chi-square test. Allele and genotype frequencies were compared between GD patients with and without GO
using the chi-square test.
Results: The genotype and allele frequencies of examined SNPs did not differ between GD patients with and without
GO. Although the genotype distribution remained nonsignificant in the sex-stratified analyses, the frequency of the T
allele at SNP rs1003199 was significantly higher in patients with GO in the male cohort (P = 6.00 × 10-3). In addition,
haplotypes of IL12B may be used to predict the risk of GO (P = 1.70 × 10-2); however, we could not prove the statistical
significance of analysis after applying the Bonferroni correction.
Conclusions: Our results provide new information that the examined IL12B gene polymorphisms may be associated
with susceptibility to GO in the Taiwan Chinese population in a sex-specific manner. This conclusion requires further
investigation.Background
Graves ophthalmopathy (GO) is a type of fibroprolifera-
tive autoimmune disease, which is characterized by
inflammation, remodeling, and expansion of the retroo-
cular fibroblasts of the eye. This disease commonly
occurs in patients with Graves disease (GD) and serves
as a major characteristic that is observed in 25–50% of
patients with GD [1-5]. Although GO may develop from
the activity of thyroid-stimulating hormone (TSH)
receptor-stimulating antibodies [6-9], which are strongly
associated with hyperthyroidism and GO, the mechanisms
linking GD and GO remain largely elusive [10-12]. Re-
cently, studies have suggested that cytokines may play a
crucial role in regulating the development of GD and GO* Correspondence: d0704@mail.cmuh.org.tw
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reproduction in any medium, provided the or[13]; however, the detailed mechanisms thereof remain
largely unclear.
Interleukin 12B (IL12B; OMIM 161561), which is
located on chromosomal region 5q33.3, encodes the p40
subunit of the cytokines IL12 and IL23, which play a
pivotal role in both innate and adaptive immunity [14].
Although the role of interleukins in the development of
GO in GD patients is little known, thyroid hormones
have been known to increase the secretion of IL12,
which regulates dendritic cell maturation and function
[15]. IL12 has been reported to be overexpressed during
the active phase of GD and GO [16,17]. On the other
hand, IL23 expression could be induced in fibroblast-
like synoviocytes through active IL1B, a well-known
GO-related cytokine in rheumatoid arthritis, in AP-
1–dependent and nuclear factor-kappa B–dependent
pathways [18-21]. These studies implied that p40, which
is encoded by IL12B, might be involved in regulating
inflammation.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Inclusion/exclusion criteria
Criteria Details
Inclusion Patients must understand risks and benefits of the protocol
and be able to give informed consent.
Patient is a self-reported non-aboriginal Taiwanese,
and none of the parents and grand-parents has aboriginal
background.
Patients must satisfy the diagnostic criteria of Graves
disease at the time of examination.
Exclusion Patients typical clinical features of hyperthyroidism, diffuse
enlargement of the thyroid gland, increased free thyroxine
or triiodothyronine levels, suppressed thyroid stimulating
hormone levels, positive thyrotrophin-receptor
autoantibodies, and with or without antimicrosomal
or antithyroglobulin antibodies.
Patient is unable to understand or give informed consent.
Patients who had pregnancy or had delivered a
baby/babies within one year.
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(SNPs) in IL12B have been associated with various im-
mune dysregulations such as systemic lupus erythemato-
sus [22], type 1 diabetes [23], psoriasis and psoriatic
arthritis [24], and GD [25]. Although the SNPs and ex-
pression of IL12B may be associated with autoimmune
thyroid diseases, especially GD and GO in Western male
populations [26,27], a genetic association between IL12B
and GO in oriental populations has not been identified
[28]. The aim of this study was to investigate the fre-
quency of IL12B variants among GD patients and correl-




A study population of 471 GD patients with or without
GO from China Medical University Hospital in Taiwan
were enrolled using the inclusion/exclusion criteria sum-
marized in Table 1, which has been published elsewhere
[18,29,30]. All the methods followed the tenets of theTable 2 Eight single nucleotide polymorphisms in the IL12B g
without Graves ophthalmopathy
SNPs Position in IL12B Chromosome po
rs2195940 Intron 5 158744352
rs2853696 Intron 5 158744660
rs2421047 Intron 4 158746307
rs2853694 Intron 3 158749088
rs2569254 Intron 1 158751249
rs1003199 Intron 1 158755566
rs7709212 Promoter 158764177
rs6868898 Promoter 158764420
SNP positions in the IL12B gene were numbered upstream (+) or downstream (−) fr
to the sequence of NCBI database (built 37.1). SNP, single nucleotide polymorphismDeclaration of Helsinki. All participants signed the con-
sent form approved by the Institutional Review Board of
the China Medical University Hospital. GO was mea-
sured by the Hertel exophthalmometer. Patients who
satisfied the NOSPECS system recommended by the
American Thyroid Association [31] were classified as
the GO group: (1) normal upper eyelid position 1.5 mm
below the superior limbus and normal lower eyelid pos-
ition at the level of the inferior limbus in primary gaze
and (2) proptosis defined as the anteroposterior protru-
sion of the globe >19 mm from the lateral orbital rim in
either eye or any discrepancy in the degree of protrusion
of both eyes by >1 mm [32]. Those who did not satisfy
both criteria were classified as the non-GO group. All
individuals classified as affected were interviewed and
examined by experienced clinicians.
SNP selection
IL12B SNP genotype information from the HapMap
CHB + JPT population was downloaded in December
2008. HapMap genotypes were analyzed within Haplo-
view, and tag SNPs were selected using the Tagger func-
tion by applying (i) 0.1 as a threshold minor allele
frequency (MAF) for “tag SNPs” in the HapMap CHB +
JPT population and (ii) ≥0.6 as the Illumina score as
recommended by the manufacturer. Eight polymorphisms
within the IL12B gene were selected accordingly, including
SNPs rs2195940 (C/T at intron 5), rs2853696 (A/G at in-
tron 5), rs2421047 (A/G at intron 4), rs2853694 (A/C at
intron 3), rs2569254 (C/T at intron 1), rs1003199 (C/T at
intron 1), rs7709212 (C/T at promoter), and rs6868898
(C/T at promoter).
Genomic DNA extraction and genotyping
Blood samples were collected by venipuncture and were
subsequently subjected to genomic DNA isolation. A
genomic DNA kit (Qiagen) was used for genomic DNA
extraction. The DNA concentration of each sample was
determined before genotyping. All 8 SNPs in the IL12Bene identified from 471 Graves disease patients with or









om the IL12B transcription initiation site. Chromosome positions were referred
; Hwpval, Hardy-Weinberg equilibrium P value; MAF, minor allele frequency.
Table 3 Frequencies of genotypes and alleles of single
nucleotide polymorphisms in the IL-12B gene in Graves
disease patients with or without Graves ophthalmopathy
SNPs GD/non-GO GD/GO P value a
Number (%) Number (%)
rs2195940
C/C 247 (91.14) 185 (92.50) 0.60
C/T 24 (8.86) 15 (7.50)
T/T 0 (0.00) 0 (0.00)
C 518 (95.57) 385 (96.25) 0.61
T 24 (4.43) 15 (3.75)
rs2853696
A/A 0 (0.00) 0 (0.00) –
A/G 0 (0.00) 0 (0.00)
G/G 271 (100.00) 200 (100.00)
A 0 (0.00) 0 (0.00) –
G 542 (100.00) 400 (100.00)
rs2421047
A/A 56 (20.66) 46 (23.00) 0.62
A/G 145 (53.51) 98 (49.00)
G/G 70 (25.83) 56 (28.00)
A 257 (47.42) 190 (47.50) 0.98
G 285 (52.58) 210 (52.50)
rs2853694
A/A 126 (46.49) 92 (46.00) 0.99
A/C 121 (44.65) 90 (45.00)
C/C 24 (8.86) 18 (9.00)
A 373 (68.82) 274 (68.50) 0.92
C 169 (31.18) 126 (31.50)
rs2569254
C/C 189 (69.74) 140 (70.00) 0.85
C/T 76 (28.04) 54 (27.00)
T/T 6 (2.21) 6 (3.00)
C 454 (83.76) 334 (83.50) 0.91
T 88 (16.24) 66 (16.50)
rs1003199
C/C 114 (42.07) 76 (38.00) 0.58
C/T 121 (44.65) 92 (46.00)
T/T 36 (13.28) 32 (16.00)
C 349 (64.39) 244 (61.00) 0.29
T 193 (35.61) 156 (39.00)
rs7709212
C/C 61 (22.51) 56 (28.00) 0.16
C/T 154 (56.83) 96 (48.00)
T/T 56 (20.66) 48 (24.00)
C 276 (50.92) 208 (52.00) 0.74
T 266 (49.08) 192 (48.00)
Table 3 Frequencies of genotypes and alleles of single
nucleotide polymorphisms in the IL-12B gene in Graves
disease patients with or without Graves ophthalmopathy
(Continued)
rs6868898
C/C 42 (15.50) 25 (12.50) 0.56
C/T 123 (45.39) 89 (44.50)
T/T 106 (39.11) 86 (43.00)
C 276 (50.92) 208 (52.00) 0.74
T 266 (49.18) 192 (48.00)
Abbreviations: GD, Graves disease; GO, Graves ophthalmopathy; CI, confidence
interval.
aP values (two-tailed) were calculated using chi-square tests with 3×2
contingency tables (genotypes; 2 d.f.) or 2×2 contingency tables (alleles; 1 d.f.).
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and ligation assay (Illumina) following the manufac-
turer’s instructions.Statistical analysis
Sample size was determined according to the previous
report [33]. We set alpha as 0.05, where 0 and 1 repre-
sent C and T respectively for alleles at rs1003199, there-
fore the mean of all 198 male patients was 0.28 and the
SD was 0.49). Associations between each SNP and GO
were assessed using the chi-square test. An exact P value
(two-tailed) < 0.05 with Bonferroni adjustment (thresh-
old P value is 0.05/n, where n is number of all independ-
ent tests at the same time) [34] was considered
statistically significant. The allelic and genotypic fre-
quencies were compared in GD patients with and with-
out GO, and the odds ratios (ORs) per allele/genotype
were estimated by applying unconditional logistic regres-
sion with a 95% confidence interval (CI). All of the
above statistical analyses were performed using PASW
Statistics 18.0 software. ORs per haplotype were calcu-
lated using Haldane’s modification of Woolf ’s equation:
OR = [(a + 1/2) × (d + 1/2)]/[(b + 1/2) × (c + 1/2)],
where a, b, c, and d represent the affected number in the
GO group, the affected number in the non-GO group,
the non-affected number in the GO group, and the non-
affected number in the non-GO group, respectively, to
avoid problems when critical entries are zero [35].
Screening for linkage disequilibrium was performed
using Haploview ver. 4.1 [36]. The best locus–locus
interaction models were detected with an estimate test-
ing accuracy of >50% consistency using the multifactor
dimensionality reduction (MDR) 1.1.0 of the open-
source MDR software package (Dartmouth Medical
School, Hanover, NH). The interaction dendrogram
was established according to a hierarchical clustering
algorithm [37-40].
Table 4 Allele frequencies of single nucleotide
polymorphism in IL-12B among male Graves disease
patients with or without Graves ophthalmopathy
SNPs GD/nonGO GD/GO P Value a Odds ratio
(95% CI) bNumber (%) Number (%)
rs2195940
C/C 43 (89.58) 49 (96.08) 0.21
C/T 5 (10.42) 2 (3.92)
T/T 0 (0.00) 0 (0.00)
C 91 (94.79) 100 (98.00) 0.22
T 5 (5.21) 2 (2.00)
rs2853696
A/A 0 (0.00) 0 (0.00) –
A/G 0 (0.00) 0 (0.00)
G/G 48 (100.00) 51 (100.00)
A 0 (0.00) 0 (0.00) –
G 96 (100.00) 102 (100.00)
rs2421047
A/A 9 (18.75) 6 (11.76) 0.18
A/G 32 (66.67) 30 (58.82)
G/G 7 (14.58) 15 (29.41)
A 50 (52.08) 42 (41.18) 0.12
G 46 (47.92) 60 (58.82)
rs2853694
A/A 26 (54.17) 21 (41.18) 0.25
A/C 20 (41.67) 24 (47.06)
C/C 2 (4.16) 6 (11.76)
A 72 (75.00) 66 (64.71) 0.11
C 24 (25.00) 36 (35.39)
rs2569254
C/C 32 (66.67) 33 (64.71) 0.38
C/T 16 (33.33) 16 (31.37)
T/T 0 (0.0) 2 (3.92)
C 80 (83.33) 82 (80.39) 0.59
T 16 (16.67) 20 (19.61)
rs1003199
C/C 23 (47.92) 13 (25.49) 0.01 1
C/T 23 (47.92) 28 (54.90) 4.11 (0.82-20.66)
T/T 2 (4.16) 10 (19.61) 8.85 (1.68-46.69)
C 69 (71.88) 54 (52.94) 6.00×10-3 1
T 27 (28.12) 48 (47.06) 2.27 (1.26-4.10)
rs7709212
C/C 14 (29.17) 12 (23.53) 0.82
C/T 27 (56.25) 31 (60.78)
T/T 7 (14.58) 8 (15.69)
C 55 (57.29) 55 (53.92) 0.63
T 41 (42.71) 47 (46.08)
Table 4 Allele frequencies of single nucleotide
polymorphism in IL-12B among male Graves disease
patients with or without Graves ophthalmopathy
(Continued)
rs6868898
C/C 5 (10.42) 10 (19.61) 0.19
C/T 18 (37.50) 23 (45.10)
T/T 25 (52.08) 18 (35.29)
C 28 (29.17) 43 (42.16) 0.06
T 68 (70.83) 59 (57.84)
Abbreviations: SNP, single nucleotide polymorphism; GD, Graves disease; GO,
Graves ophthalmopathy; CI, confidence interval.
aP values (two-tailed) were calculated using chi-square tests with 3×2
contingency tables (genotypes; 2 d.f.) or 2×2 contingency tables (alleles; 1 d.f.).
bOdds ratios and 95% CI per genotype and allele were estimated by applying
unconditional logistic regression. P values less than 0.05 were considered
significant.
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Genotypic frequencies of the IL12B polymorphisms in GD
patients
All the samples from 471 GD patients were genotyped
for the 8 SNPs in the IL12B gene. All of the tested SNPs
in this study were found to be in Hardy-Weinberg equi-
librium (P > 0.05, Table 2). To identify the SNPs asso-
ciated with clinical features of GD, including GO, goiter,
nodular hyperplasia, pretibial myxedema, and vitiligo,
the 8 SNPs within the IL12B gene were investigated.
None of these clinical features were associated with any
of the tested IL12B polymorphisms (Table 3 and data
not shown).
The IL12B polymorphism rs1003199 is significantly
associated with the development of GO in male GD
patients
In our study, there were many more female patients than
male patients (female:male, 3.8:1). Because sex ratio is
one variable that can affect the results of case–control
association studies, a sex-stratification analysis was per-
formed. Results showed that although no significant
difference between IL12B SNPs and GO in the female
patients was observed, SNP rs1003199 was significantly
associated with the development of GO in the male
GD patients: GD patients with the T allele at
rs1003199 showed a 1.27-fold increase in the risk of
developing GO compared with GD patients carrying
the C allele (P = 6.00 × 10-3; OR = 2.27, 95% CI =
1.26–4.10; Table 4). The sample size was large enough
(198 individuals) to detect the polymorphism (α =
0.05, power = 0.88). In addition, GD patients with a
T/T genotype at rs1003199 showed a 7.85-fold increase
in the risk of developing GO compared with GD
patients carrying the C/C genotype (P = 0.01; OR =
8.85, 95% CI = 1.68–46.69; Table 4). However, only
the significance of the allele distribution at rs1003199
Table 5 Summary of multifactor dimensionality reduction (MDR) models for gene-gene interaction in male Graves
disease patients with Graves ophthalmopathy
Number of factors Best candidate model Balance accuracy CV consistency X2 P value Odds ratio (95%CI)
1 rs1003199 59.47% 100/100 7.53 6.00×10-3 2.27 (1.26-4.10)
2 rs2195940 rs1003199 59.50% 76/100 7.67 6.00×10-3 2.30 (1.27-4.17)
3 rs1003199 rs7709212 rs6868898 61.40% 100/100 10.52 1.20×10-3 2.59 (1.45-4.62)
4 rs2853694 rs1003199 rs7709212 rs6868898 53.28% 100/100 12.47 4.00×10-4 2.82 (1.58-5.06)
Liu et al. Journal of Biomedical Science 2012, 19:97 Page 5 of 8
http://www.jbiomedsci.com/content/19/1/97remained after applying the Bonferroni correction.
These results indicate that male GD patients carrying
the T allele might be at a higher risk for developing
GO than patients carrying other alleles, suggesting the
possible role of IL12B in the development of GO in
the male GD patients.
Frequencies of the IL12B haplotypes and their
associations with GD and GO
Because our MDR analysis indicated that the best inter-
action model for the prediction of GO development in
male GD patients is the 3-locus model (balance accur-
acy, 61.40%; cross-validation consistency = 100/100, P =
1.20 × 10-3; Table 5), we further estimated the associ-
ation between the haplotype comprising the 3 SNPs
rs1003199, rs7709212, and rs6868898 and GO. These
results are listed in Table 6. In the male GD patients, the
frequencies of IL12B haplotypes were significantly differ-
ent (P = 1.70 × 10-2). Although haplotype-specific ana-
lysis showed that haplotypes HA5-TCC and HA7-TTC
are associated with a higher risk of GO (P = 0.03; OR:
4.13 and P = 0.02; OR: 10.89; respectively), and haplo-
type HA2-CCT is associated with a lower risk of devel-
oping GO (P = 0.03; OR: 0.51), we could not prove the
statistical significance of the analysis after applying the
Bonferroni correction.Table 6 Estimated frequencies of the haplotypes inferred from
Graves disease patients with or without Graves ophthalmopa
Haplotype SNP GD/non
rs1003199 rs7709212 rs6868898 Number
HA1 C C C 17 (17.71
HA2 C C T 34 (35.42
HA3 C T C 8 (8.33)
HA4 C T T 10 (10.42
HA5 T C C 0 (0.00)
HA6 T C T 4 (4.17)
HA7 T T C 3 (3.13)
HA8 T T T 20 (20.83
Abbreviations: GD, Graves disease; GO, Graves ophthalmopathy; CI, confidence inte
aP values (two-tailed) were calculated using chi-square tests with 8×2 contingency
bP values (two-tailed) were calculated using chi-square tests with 2×2 contingency
cOdds ratio was calculated using Haldane’s modification of Woolf’ equation.Discussion
Several reports have documented that genetic factors
may play a role in the development of GO [12,13,41,42]:
the susceptibility genes for GO may include those en-
coding the major histocompatibility complex (HLA) class
I and class II molecules [12], cytotoxic T-lymphocyte-
associated protein 4 (CTLA4) [12], cell surface molecules
intercellular adhesion molecule 1 (ICAM1) [43], and in-
tegrin alpha E (ITGAE) [29], as well as a variety of
immunomodulatory genes, including those encoding the
cytokines interferon gamma (IFNG) [26,44], tumor ne-
crosis factor (TNF) [26,45], and interleukin 1 beta (IL1B)
[18-20]. IL12B has been identified to possibly influence
the development of autoimmune thyroid diseases and
the related ophthalmopathy in male patients in the
Western world [26,27], but it has not yet been deeply
examined in Oriental patients [28]. In this study, we
investigated whether IL12B SNPs contributed to the de-
velopment of GO in a Taiwan Chinese GD population.
The results show that none of the tested IL12B SNPs
were associated with any manifestations of GD. How-
ever, the T allele at SNP rs1003199 was significantly
associated with the occurrence of GO in male patients.
Our results, in part, support the hypothesis that SNPs of
pro-inflammatory cytokines may be related to GO
development.rs1003199, rs7709212 and rs6868898 among male
thy
GO GD/GO P Value a P Value b Odds ratio c
(%) Number (%)
) 22 (21.57) 1.70 × 10-2 0.50 1.27
) 22 (21.57) 0.03 0.51
4 (3.92) 0.19 0.48
) 6 (5.88) 0.24 0.55
5 (4.90) 0.03 10.89
6 (5.88) 0.58 1.38
12 (11.76) 0.02 3.69
) 25 (24.51) 0.54 1.23
rval.
tables (haplotypes; 7 d.f.).
tables (haplotypes; 1 d.f.).
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has reasonable power for detecting interactions. Com-
pared to the conventional statistical approaches, MDR
was a novel, nonparametric, and genetic model–free ap-
proach that was developed specifically to detect not only
interactions within or among genes but also interactions
between genes and the environment. The MDR method
has been used in several diseases such as cancers and
inherited diseases [46,47]. However, a disadvantage of
this method is that it overemphasizes the large dissimi-
larities and does not appropriately represent the small
dissimilarities. Here, we used the MDR method to iden-
tify the interaction between 3 SNPs, including rs1003199
in intron 1 and rs7709212 and rs6868898 in the pro-
moter, and GO. In addition, our preliminary results from
a database search (MiRbase, http://www.mirbase.org/
search.shtml) suggest that these SNPs may be miRNA
targets. The C allele at rs6868898 showed higher similar-
ity with miRNA sequences than the T allele at
rs6868898. Moreover, only the T allele at rs1003199 and
the T allele at rs7709212, but not the C allele at
rs1003199 and the C allele at rs7709212, showed a simi-
larity with miRNA sequences (Additional file 1).
Whether these SNPs, as well as haplotypes, play a role
in the development of GO by regulating the expression
of the IL12B gene or the stability of the mRNA by
miRNA needs further investigation.
The SNP rs6887695, which is located in the pro-
moter region of the IL12B gene, may be associated
with GO [26,27]. Although it was not selected under
our SNP criteria, we also tried to analyze its genotype
distribution in our patients, but we failed to find a sta-
tistically significant association between SNP rs6887695
and GO. Ethnic differences may be a reason for this
discrepancy. Although the results presented here pro-
vide new information that may facilitate the under-
standing of the pathogenesis of GO, additional studies
are necessary to confirm this finding in a larger sam-
ple and ideally, in a second group of affected and un-
affected individuals.
The results of this study also provide novel information
for identifying the mechanisms underlying the pathogen-
esis of GO. It has long been established that GO is a
complex disease with a variety of weak-effect genes that
are influenced by a wide range of environmental factors
such as sex, iodine status, smoking, infectious agents,
and stress. However, the reasons for the significant fe-
male preponderance of GD and GO are not well under-
stood, but they may include skewed X chromosome
inactivation [48], fetal microchimerism [49], or sex hor-
mone effects [50]. In view of the significant sex-specific
variation in GO, genetic factors may influence the estab-
lishment of differential risk between affected women and
men. This study demonstrated that the polymorphismsof the IL12B gene may influence the development of GO.
However, because of the lack of a larger sample size and
published functional studies on these polymorphisms,
the mechanisms of the associated polymorphisms need
to be fully examined for their capacity to alter the GO
phenotype. In addition, to confirm the disease-associated
SNPs, further investigations on the role of the IL12B
gene in GO development at the molecular level are
warranted.
Conclusion
In summary, this study showed that the IL12B
polymorphisms may be associated with GO in Taiwan
Chinese GD patients in a sex-specific manner. Whether
these results can provide valuable insights requires fur-
ther genetic and biological studies of the specific SNPs
and haplotypes.
Additional file
Additional file 1: Table S1. Prediction of polymorphisms of biological
relevance in miRNA target sites.
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